Predict your next investment

Asset/Investment Management
brainib.com

See what CB Insights has to offer

Investments

4

Portfolio Exits

1

Funds

2

About Brain Asset Management

Brain Asset Management (브레인자산운용) is an asset manager and product developer for institutional investors and high-net-worth individuals. The firm has three major business areas: hedge fund, personal managed account, and investment advisory.

Brain Asset Management Headquarter Location

Shinhan Investment Tower, 26F 70, Yeoui-daero, Yeongdeungpo-gu

Seoul, 07325,

South Korea

+82-2-6277-5000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Brain Asset Management News

PDC*line Pharma Raises €17.5M in Series B2 Financing Round

Dec 6, 2021

PDC*line Pharma , a Liege, Belgium- and Grenoble, France-based clinical stage biotech company developing a new class of potent and scalable active off-the-shelf cancer vaccine, completed a €17.5M Series B2 round of financing. This round was led by Korea Investment Partners with participation from Alpha Holdings, Brain Asset Management and Hansongneotech Co. and existing investors Noshaq Group, Sambrinvest, SFPI-FPIM, SRIW and Smart Korea UTC Bio-Healthcare Venture Fund. Founded in 2014 as a spin-off from the French Blood Bank (EFS) and led by Eric Halioua, CEO, PDC*line Pharma is a clinical-stage biotech company that develops an innovative class of active immunotherapies for cancers, based on a GMP-grade allogeneic therapeutic cell line of plasmacytoid dendritic cells (PDC*line). The technology can potentially be applied to any type of cancer. Following a first-in-human phase I feasibility study in melanoma, PDC*line Pharma focuses on the development of PDC*lung01, a candidate for Non-Small-Cell Lung Cancer (NSCLC) currently in phase I/II trials, and PDC*neo with neoantigens in preclinical development. The objectives of the phase I/II study (PDC-LUNG-101) are to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the drug candidate, PDC*lung01, associated or not with anti-PD-1 treatment in NSCLC. A total of 64 evaluable HLA-A*02:01 positive NSCLC patients are expected in clinical centers in Belgium, France, Germany, the Netherlands and Poland. PDC*lung01 consists of PDC*line professional antigen-presenting cells loaded with HLA-A2 restricted peptides, derived from seven shared tumor antigens. The company has a staff of 27, raised more than €52M in equity and non-dilutive funding. In March 2019, PDC*line Pharma granted an exclusive license to the LG Chem Life Sciences company in South Korea and an exclusive option in other Asian countries, for the development and commercialization of the PDC*lung01 cancer vaccine for lung cancer. The total deal is worth $123M, plus tiered royalties on net sales in Asia. FinSMEs 06/12/2021

Brain Asset Management Investments

4 Investments

Brain Asset Management has made 4 investments. Their latest investment was in PDC*line Pharma as part of their Series B - II on December 12, 2021.

CBI Logo

Brain Asset Management Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/6/2021

Series B - II

PDC*line Pharma

$13.7M

Yes

3

6/15/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

11/10/2020

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

4/30/2019

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/6/2021

6/15/2021

11/10/2020

4/30/2019

Round

Series B - II

Series C

Unattributed VC

Series C

Company

PDC*line Pharma

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$13.7M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

10

10

10

Brain Asset Management Portfolio Exits

1 Portfolio Exit

Brain Asset Management has 1 portfolio exit. Their latest portfolio exit was Tium Bio on November 22, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/22/2019

IPO

1

Date

11/22/2019

Exit

IPO

Companies

Valuation

Acquirer

Sources

1

Brain Asset Management Fund History

2 Fund Histories

Brain Asset Management has 2 funds, including Baekdu 1st Hedge Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

Baekdu 1st Hedge Fund

Hedge

Open

1

Taebaek 2nd Hedge Fund

Subscribe to see more

Subscribe to see more

10

Closing Date

Fund

Baekdu 1st Hedge Fund

Taebaek 2nd Hedge Fund

Fund Type

Hedge

Subscribe to see more

Status

Open

Subscribe to see more

Amount

Sources

1

10

Brain Asset Management Team

2 Team Members

Brain Asset Management has 2 team members, including current Chief Executive Officer, Keon Young Park.

Name

Work History

Title

Status

Keon Young Park

Chief Executive Officer

Current

Tae Joon Kim

Senior Director

Current

Name

Keon Young Park

Tae Joon Kim

Work History

Title

Chief Executive Officer

Senior Director

Status

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.